Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Early on, typically no symptoms are seen. Later symptoms may include abnormal vaginal bleeding, pelvic pain or pain during sexual intercourse. While bleeding after sex may not be serious, it may also indicate the presence of cervical cancer.

Human papillomavirus infection (HPV) causes more than of cases; most people who have had HPV infections, however, do not develop cervical cancer. Other risk factors include smoking, a weak immune system, birth control pills, starting sex at a young age, and having many sexual partners, but these are less important. Cervical cancer typically develops from precancerous changes over 10 to 20 years. The cervical cancer cases are squamous cell carcinomas, are adenocarcinoma, and a small number are other types. Diagnosis is typically by cervical screening followed by a biopsy. Medical imaging is then done to determine whether or not the cancer has spread.

The HPV vaccines protect against two to seven high-risk strains of this family of viruses and may prevent up to 90% of cervical cancers. As a risk of cancer still exists, guidelines recommend continuing regular Pap tests. Other methods of prevention include having few or no sexual partners and the use of condoms. Cervical cancer screening using the Pap test or acetic acid can identify precancerous changes, which when treated, can prevent the development of cancer.^] Treatment may consist of some combination of surgery, chemotherapy, and radiation therapy

The cervical cancer is both the fourth-most common cause of cancer and the fourth-most common cause of death from cancer in women.  an estimated cases of cervical cancer occurred, with huge numbers in deaths.  It is one of the most common causes of cancer death. The widespread use of cervical screening programs has dramatically reduced rates of cervical cancer. In medical research, the most famous immortalized cell line, was developed from cervical cancer cells of a woman named Henrietta Lacks.

Journal of Cancer Research and Immuno-Oncology is an open access rapid peer reviewed journal in the field of cancer research. Journal announces papers for the upcoming issue. Interested can submit their manuscript through online portal.

Submit manuscript at https://www.longdom.org/submissions/cancer-research-immuno-oncology.html or send as an e-mail attachment to the Editorial Office at immunooncology@emedscholar.com

Media contact:

Maegan smith

Managing Editor

Journal of Cancer Research and Immuno-Oncology

Mail ID: immunooncology@emedscholar.com

WhatsApp:  180-23424982